The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes

Summary The Central and Eastern Europe (CEE) region is attractive to drug manufacturers for its large cumulative population, evolving price and market access (P&MA) landscape, and relatively high willingness-to-pay (WTP) thresholds International Reference Pricing (IRP) policies continues to be one of the most important criteria in price decision-making in CEE…

STRIMVELIS™ – The Proof Is In The Messaging

In an unprecedented move, GBR’s (United Kingdom) NICE (National Institute for Health and Care Excellence) recently recommended NHS (National Health Services) funding of $GSK’s gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” – at EUR 594,000 (ex-VAT2 price, about USD 700,000). Importantly,…

Page 1 of 3123